Summit Therapeutics Inc. (SMMT)
| Market Cap | 10.72B -46.0% |
| Revenue (ttm) | n/a |
| Net Income | -856.09M |
| EPS | -1.12 |
| Shares Out | 797.75M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,817,707 |
| Open | 12.79 |
| Previous Close | 12.80 |
| Day's Range | 12.72 - 13.56 |
| 52-Week Range | 12.25 - 30.98 |
| Beta | -1.26 |
| Analysts | Buy |
| Price Target | 28.36 (+111.01%) |
| Earnings Date | Jul 23, 2026 |
About SMMT
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth facto... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 17 analysts, the average rating for SMMT stock is "Buy." The 12-month stock price target is $28.36, which is an increase of 111.01% from the latest price.
News
Summit Therapeutics price target lowered to $15 from $17 at Jefferies
Jefferies lowered the firm’s price target on Summit Therapeutics (SMMT) to $15 from $17 and keeps a Hold rating on the shares, contending that the “key update” in the Q2…
H.C. Wainwright keeps Neutral on Summit Therapeutics after Q2 report
H.C. Wainwright analyst Mitchell Kapoor reiterates a Neutral rating on Summit Therapeutics (SMMT) following the Q2 report. While HARMONi-3 enrollment is complete, slower event rates push the squamous ...
Summit Therapeutics price target lowered to $38 from $45 at Stifel
Stifel analyst Dara Azar lowered the firm’s price target on Summit Therapeutics (SMMT) to $38 from $45 and keeps a Buy rating on the shares. The firm thinks “timing is…
Summit Therapeutics price target lowered to $38 from $40 at Guggenheim
Guggenheim analyst Brad Canino lowered the firm’s price target on Summit Therapeutics (SMMT) to $38 from $40 and keeps a Buy rating on the shares. Management still expect to conduct…
Summit Therapeutics reiterates ‘substantial doubt’ as going concern
Summit Therapeutics (SMMT) reiterated concerns about remaining a going concern in its June quarter SEC filing. The company used the same language in its March quarter earnings filing. Summit said,…
Summit Therapeutics says will need to raise additional capital
In its 10-Q filing, Summit Therapeutics (SMMT) stated: “The Company’s cash and cash equivalents and short-term investments are not sufficient to fund the Company’s planned operations for a period of…
Summit Therapeutics Earnings Call Transcript: Q2 2026
Ivonescimab continues to demonstrate robust clinical efficacy and safety across global phase III trials, with consistent OS benefit in both Asian and Western populations. Financially, the company maintains a strong cash position and is preparing for a potential U.S. launch pending FDA review.
Summit Therapeutics Earnings release: Q2 2026
Summit Therapeutics released its Q2 2026 earnings on July 23, 2026, summarizing the period's financial results.
Summit Therapeutics Quarterly report: Q2 2026
Summit Therapeutics has published its Q2 2026 quarterly earnings report on July 23, 2026.
Summit Therapeutics Slides: Q2 2026
Summit Therapeutics has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 23, 2026.
Summit Therapeutics: Enrollment in both HARMONi-3 cohorts complete
Enrollment in both the squamous and non-squamous NSCLC cohorts of the global HARMONi-3 study is now complete. The number of PFS events needed in the squamous cohort for the primary…
Summit Therapeutics reports Q2 EPS (28c), consensus (21c)
“The clinical momentum of ivonescimab continues to build, with two recent key data readouts that significantly bolster our development progress. At ASCO, the landmark HARMONi-6 results established the...
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today reported its financial results for the second quarter and six months ended June 30, 2026 and provided an update on clini...
Arcus, Summit enter into clinical trial collaboration over kidney cancer
Arcus Biosciences (RCUS) and Summit Therapeutics (SMMT) announced a clinical trial collaboration to evaluate the safety and efficacy of Arcus’s casdatifan, an investigational hypoxia-inducible factor ...
Arcus Biosciences and Summit Therapeutics Enter Into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer
HAYWARD, Calif. & MIAMI--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therap...
Arcus Biosciences and Summit Therapeutics Enter into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer
HAYWARD, Calif. & MIAMI--(BUSINESS WIRE)---- $SMMT--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combinat...
Summit Therapeutics reports results from global Phase III HARMONi clinical trial
Summit Therapeutics (SMMT) announced results of an updated overall survival, or OS, analysis from the global Phase III HARMONi clinical trial featuring the novel, potential first-in-class investigatio...
Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi Study
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (Nasdaq: SMMT) today announced results of an updated overall survival (OS) analysis from the global Phase III HARMONi clinical trial featurin...
Summit Therapeutics to Host Second Quarter 2026 Financial Results & Operational Progress Call on July 23, 2026
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (Nasdaq: SMMT) will host a conference call to announce its second quarter 2026 financial results and provide an update on operational progres...
Summit Therapeutics signs agreement to sell ridinilazole to Biossil
Summit Therapeutics (SMMT) signed an agreement with Toronto-based Biossil, Inc. for the sale of ridinilazole, an investigational Phase III precision antibiotic owned by Summit. Biossil is an artificia...
Summit Therapeutics Signs Agreement to Sell Phase III Asset Ridinilazole to Biossil, Inc.
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced it has signed an agreement with Toronto-based Biossil, Inc. for the sale of ridinilazole, an investigational P...
Summit Therapeutics withdraws proposed underwritten public offering
In a regulatory filing, Summit Therapeutics (SMMT) announced that effective June 10, 2026 it has withdrawn its previously announced proposed underwritten public offering of securities due to market co...
Summit Therapeutics falls -10.2%
Summit Therapeutics (SMMT) is down -10.2%, or -$1.46 to $12.83.
Summit Therapeutics put volume heavy and directionally bearish
Bearish flow noted in Summit Therapeutics (SMMT) with 1,656 puts trading, or 1.2x expected. Most active are 6/12 weekly 13 puts and Jul-26 13 puts, with total volume in those…
Summit Therapeutics Transcript: AGM 2026
The meeting covered board elections, auditor ratification, executive compensation, and a stock plan amendment, all of which were approved by shareholders. No questions were raised during the Q&A session.